N-terminal-pro-brain natriuretic peptide, but not brain natriuretic peptide, is increased in patients with severe obesity

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 2, 2007, Pages 153-158

  Fernandes, Fabio ^a   Ramires, F J A ^a   Buck, P C ^a   Almeida, I J ^a   Rabelo, R ^b   Dantas, S A ^a   Salemi, V M C ^a   Halpern, A ^a   Mady, C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fleury   (Brazil)

Author keywords

Brain natriuretic peptide; Heart failure; NT proBNP; Obesity

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE DURATION; DISEASE SEVERITY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMAN; MALE; OBESITY; PROTEIN BLOOD LEVEL; STUDENT T TEST; WAIST CIRCUMFERENCE;

EID: 33846901575     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006005000066     Document Type: Article

References (22)

1. Coviello JS, Nystrom KV. Obesity and heart failure. J Cardiovasc Nurs 2003; 18: 360-366.
2. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
3. Alpert MA, Terry BE, Kelly DL. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. Am J Cardiol 1985; 55: 783-786.
4. Smith HL, Willius FA. Adiposity of the heart. Arch intern Med 1933; 52: 911-931.
5. Amad KH, Brennan JC, Alexander JK, The cardiac pathology of chronic exogenous obesity. Circulation 1965; 32: 740-745.
6. Nakajima T, Fujioka S, Tokunaga K, Hirobe K, Matsuzawa Y, Tarui S. Noninvasive study of left ventricular performance in obese patients: influence of duration of obesity. Circulation 1985; 71: 481-486.
7. Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen MV, Massey CV, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995; 76: 1194-1197.
8. Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004; 29: 707-769.
9. Machado M, Falcão LM, Ravara L. The clinical role of natriuretic peptides - importance of BNP and NT-proBNP. Implications in heart failure and acute coronary syndrome. Rev Port Cardiol 2004; 23: 1005-1032.
10. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 2004; 6: 289-293.
11. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
12. Sahn DJ, DeMaria AN, Kisslo J, Weyman A. The Committee on M-mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
13. Alexander JK, Dennis EW, Smith WG, Mad KH, Duncan WC, Austin RC. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull 1962; 1: 39-44.
14. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321: 225-236.
15. Nielsen SL. Measurement of blood flow in adipose tissue from the washout of Xenon-133 after atraumatic labelling. Acta Physiol Scand 1972; 84: 187-196.
16. Vasan RS. Cardiac function and obesity. Heart 2003; 89: 1127-1129.
17. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600.
18. Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Mahr B, Dunky A, et al. Effect of gastric banding on aminoterminal pro-brain natriuretic peptide in the morbidly obese. Obes Res 2003; 11: 695-698.
19. Herrmann-Arnhof KM, Hanusch-Enserer U, Kaestenbauer T, Publig T, Dunky A, Rosen HR, et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin Chem 2005; 51: 138-143.
20. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287-296.
21. Adams JP, Murphy PG. Obesity in anaesthesia and intensive care. Br J Anaesth 2000; 85: 91-106.
22. Grandi AM, Laurita E, Selva E, Piantanida E, Imperiale D, Giovanella L, et al. Natriuretic peptides as markers of preclinical cardiac disease in obesity. Eur J Clin Invest 2004; 34: 342-348.